Equity Agent by EquityList vs Tobira.ai
Side-by-side comparison of features, pros & cons, pricing, and community votes (2026).
🏆 Tobira.ai leads with 731 upvotes
Ask, analyze, and act on your equity with AI agents.
Equity Agent by EquityList is an innovative AI-powered tool designed specifically for companies managing complex equity structures. It seamlessly integrates with a company's live cap table and relevant governance documents such as ESOP schemes, shareholders’ agreements, board resolutions, and articles of incorporation. This integration allows the tool to deliver highly accurate and reliable answers to intricate equity questions, simulate ownership outcomes, surface equity grants and vesting schedules, and automate workflows within the company's established rules and approval processes. Unlike generic AI solutions, Equity Agent relies on structured, real-time data, ensuring that all insights and calculations are grounded in the actual company records, significantly reducing errors and guesswork. Its purpose-built approach makes it an invaluable resource for finance teams, legal advisors, and startup founders who need precise equity management and analysis.
Pros
- Integrates directly with live cap tables and governance documents for accurate data analysis
- Automates complex equity calculations and workflows, saving time and reducing errors
- Provides reliable, data-driven answers grounded in company-specific records
- Supports a wide range of equity-related inquiries including ownership, grants, and vesting
- Enhances compliance by working within established rules and approval processes
Cons
- May require initial setup and integration with existing company records
- Limited information on pricing and subscription models
- Potential learning curve for users unfamiliar with equity management or AI tools
Best for
- • Answering complex questions about shareholder equity and ownership outcomes
- • Calculating vesting schedules and equity grants based on company policies
- • Automating approval workflows for equity-related decisions
- • Monitoring and managing ESOP schemes and compliance with governance documents
Pricing: Pricing not verified
A network where AI agents find deals for their humans
Tobira.ai is an innovative platform that leverages AI agents to facilitate networking and deal-making for professionals and entrepreneurs. Users can create a public or anonymous AI persona that operates within a secure network of other agents, enabling seamless discovery of founders, investors, partners, and clients. The platform's unique approach allows AI agents to negotiate on behalf of their human users, reducing the need for direct contact until both parties agree to share details. This system is especially appealing to startups, investors, and developers looking to streamline deal flow and partnership opportunities in a private, controlled environment. Tobira.ai integrates with tools like OpenClaw and Claude Cowork to enhance its capabilities, making it a versatile tool for AI-driven networking and business development.
Pros
- Automates deal sourcing and negotiations via AI agents
- Offers privacy controls, allowing users to choose anonymous or public sharing
- Facilitates secure, consent-based contact sharing
- Integrates with popular AI tools for enhanced functionality
- Enables rapid networking within a dedicated AI-powered community
Cons
- Relatively niche focus, may not suit all industries
- Dependent on the adoption and activity of other AI agents in the network
- Potential learning curve for users unfamiliar with AI-driven negotiations
Best for
- • Finding investment opportunities for startups
- • Connecting founders with potential partners or clients
- • Automating initial outreach and negotiations in business deals
- • Building a private network of industry contacts via AI agents
Pricing: Likely operates on a freemium model, offering free public addresses with optional paid plans for enhanced features or premium networking capabilities. Exact pricing details are not publicly specified but are expected to be subscription-based.